[Clinical relevance of the determination of TSH-binding inhibitory immunoglobulins (TBII) in patients with immunogenic hyperthyroidism in methimazole therapy].
In 38 patients with immunogenic hyperthyroidism a follow-up was performed to estimate the value of TBII before, during and after methimazole therapy. Before therapy increased TBII were detectable in 37 patients (94.4%). After 12 months methimazole therapy 25 patients had TSH-receptor antibodies (66%) within the normal range. In 13 patients positive antibody titres were found. In most cases persistence of increased TBII-values during drug treatment was an indicator of the persistence of active hyperthyroidism (10 of 13 patients). In the rule a disappearance of TBII-activity was combined with a functional remission (22 of 25 patients). Prolonged demonstration of TBII-activity in conjunction with persistence of hyperthyroidism should lead to ablative measures. In contrast to this medical therapy should be finished in patients with immunological and functional remission. Though in the further follow-up a recurrence of the immunological base of the disease with a functional and clinical relapse is possible.
D001323:Autoantibodies / Q000032:analysis; D005500:Follow-Up Studies; D006111:Graves Disease / Q000188:drug therapy / Q000276:immunology*; D006801:Humans; D007074:Immunoglobulin G / Q000378:metabolism*; D018828:Immunoglobulins, Thyroid-Stimulating; D008713:Methimazole / Q000627:therapeutic use*; D011869:Radioligand Assay; D011989:Receptors, Thyrotropin / Q000276:immunology; D013961:Thyroid Gland / Q000276:immunology*; D013973:Thyrotropin-Releasing Hormone
D001323:Autoantibodies; D007074:Immunoglobulin G; D018828:Immunoglobulins, Thyroid-Stimulating; D011989:Receptors, Thyrotropin; D008713:Methimazole; D013973:Thyrotropin-Releasing Hormone
Klinische Relevanz der Bestimmung von TSH-Bindungs-inhibierenden Immunglobulinen (TBII) bei Patienten mit immunogener Hyperthyreose unter Methimazoltherapie.